Abstract
Hypoxia, a common condition of the tumor microenvironment, is associated with poor patient prognosis, tumor cell migration, invasion and metastasis. Recent evidence suggests that hypoxia alters endosome dynamics in tumor cells, leading to augmented cell proliferation and migration and this is particularly relevant, because endosomal components have been shown to be deregulated in cancer. The early endosome protein Rab5 is a small GTPase that promotes integrin trafficking, focal adhesion turnover, Rac1 activation, tumor cell migration and invasion. However, the role of Rab5 and downstream events in hypoxia remain unknown. Here, we identify Rab5 as a critical player in hypoxia-driven tumor cell migration, invasion and metastasis. Exposure of A549 human lung carcinoma, ZR-75, MDA-MB-231 and MCF-7 human breast cancer and B16-F10 mouse melanoma cells to hypoxia increased Rab5 activation, followed by its re-localization to the leading edge and association with focal adhesions. Importantly, Rab5 was required for hypoxia-driven cell migration, FAK phosphorylation and Rac1 activation, as shown by shRNA-targeting and transfection assays with Rab5 mutants. Intriguingly, the effect of hypoxia on both Rab5 activity and migration was substantially higher in metastatic B16-F10 cells than in poorly invasive B16-F0 cells. Furthermore, exogenous expression of Rab5 in B16-F0 cells predisposed to hypoxia-induced migration, whereas expression of the inactive mutant Rab5/S34N prevented the migration of B16-F10 cells induced by hypoxia. Finally, using an in vivo syngenic C57BL/6 mouse model, Rab5 expression was shown to be required for hypoxia-induced metastasis. In summary, these findings identify Rab5 as a key mediator of hypoxia-induced tumor cell migration, invasion and metastasis.
Keywords: Rab5, hypoxia, migration, metastasis, tumor
INTRODUCTION
Metastasis is a multifactorial process that depends on a variety of cellular traits, including enhanced cell migration and the ability to invade surrounding tissues [1]. Accumulating evidence indicates that tumor cell migration and invasion are strongly influenced by microenvironmental cues, such as the composition of the extracellular matrix, the lack of nutrients and changes in oxygen availability [2, 3]. Particularly, low oxygen tension or hypoxia is associated not only with poor patient prognosis [4, 5], but also with metastasis by stimulating events leading to angiogenesis and tissue invasion [6]. The mechanisms implicated in hypoxia-induced metastasis include those dependent on and independent of the Hypoxia Inducible Factor (HIF) [7, 8], a transcription factor that is stabilized during hypoxia and promotes the expression of a wide array of genes implicated in cell adaptation [7]. Alternatively, hypoxia stimulates tumor cell migration and invasion via increased activation of matrix metalloproteinases, remodeling of the extracellular matrix [3], activation of signaling molecules including Focal Adhesion Kinase (FAK) and Rac1 [9–11], and by activating pathways initiated by growth factors [12], amongst other events (Reviewed in [6]). Interestingly, several of these processes initiated by hypoxia are known to be affected by alterations in endosomal proteins [13]. In particular, hypoxia has been shown to promote re-localization of Rab11-positive recycling endosomes in a microtubule-dependent manner, leading to increased surface expression of integrin α6β4 and invasion of breast tumor cells [14]. These observations are intriguing, as changes in expression or activity of Rab proteins and their effectors have been identified as a recurrent phenomenon in cancer [15, 16]. However, besides the aforementioned studies, the connection between hypoxia and Rab proteins is poorly understood.
Rabs are small GTPases that regulate different aspects of intracellular traffic, including vesicle formation, endosome fusion, sorting, tethering and transport along microtubules [17]. Given their pleiotropic functions, several Rabs have been shown to be either up-regulated or down-regulated in cancer [18]. In this respect, the early endosome protein Rab5 is particularly interesting, because it is required for different aspects of tumor cell metastasis [19]. Rab5 promotes cell migration and invasion by stimulating focal adhesion (FA) turnover [20, 21], FAK phosphorylation [20], Rac1 activity [22, 23] and matrix metalloproteinase release/activation [20, 24]. Most of these events are dependent of Rab5 functional activity (i.e. GTP-loading), which has encouraged different groups to identify intracellular pathways involved in both Rab5 activation and tumor cell migration and invasion [21–23, 25–27]. However, despite the widely recognized effect of microenvironmental cues on tumor cell dissemination, the role of extra-cellular stimuli on Rab5 function remains unexplored. In particular, the potential connection between hypoxia and Rab5 is an intriguing possibility, as both are known to promote tumor cell migration, invasion and metastasis by similar signaling mechanisms. In this study, we show that hypoxia stimulates Rab5 activity in a HIF-1α-dependent manner, and induces re-localization of Rab5 to FAs in tumor cells. Interestingly, hypoxia was found to increase FAK phosphorylation, Rac1 activity and tumor cell migration in a Rab5-dependent manner. Finally, Rab5 was shown to be required for invasion and metastasis induced by hypoxia.
RESULTS
Hypoxia promotes Rab5-GTP loading and re-localization in tumor cells
Because hypoxia is known to stimulate the metastasis of tumor cells [6], and Rab5 is an important mediator of tumor cell migration and invasion [19, 24], we evaluated the possibility that a connection may exist between hypoxia and Rab5. To this end, different tumor cell lines, including A549 human lung carcinoma, MDA-MB-231, ZR75 and MCF7 human breast cancer and B16-F10 mouse melanoma cells, were subjected to either normoxia (20% oxygen) or hypoxia (1% oxygen) for 24 hours, and Rab5-GTP levels were measured in pull-down assays. Interestingly, hypoxia induced a substantial increase in Rab5-GTP levels in A549 (3-fold increase), MDA-MB-231 (2-fold increase), MCF-7 (4-fold increase), ZR-75 (2-fold increase) and B16-F10 cells (3-fold increase), when compared to normoxia (Figure 1A). A more detailed analysis in A549 cells revealed that Rab5 activation by hypoxia was biphasic, whereby Rab5-GTP levels peaked after 6 and 24 hours of hypoxia, reaching maximum values at 24 hours (Figure 1B). Intriguingly, augmented Rab5-GTP levels induced by hypoxia were not associated with changes in total Rab5 (Figure 1C), but these changes depended on the Hypoxia Inducible Factor, HIF-1α, since targeting of HIF-1α with either siRNA (Figure 1D, 1E) or shRNA approaches (Figure 1F, 1G) prevented Rab5-GTP loading during hypoxia, without any significant changes in total Rab5 levels.
Our previous studies have shown that Rab5 activation in tumor cells is followed by its re-localization to the cell periphery, which is associated with increased cell migration [20, 27, 28]. Thus, we evaluated the localization of active Rab5 during hypoxia, using the mCherry-R5BD construct, which was previously shown to co-localize with Rab5-GTP, but not Rab5-GDP [20]. A549 cells were co-transfected with GFP-actin and mCherry-R5BD or mCherry alone, and then subjected to normoxia or hypoxia for 24 hours. As anticipated, substantial accumulation of mCherry-R5BD, but not mCherry alone, was observed at the periphery of cells exposed to hypoxia (Figure 2A). Of note, re-localization of mCherry-R5BD correlated with peripheral accumulation of endogenous Rab5 (Suppl. Figure 1A), but not other early endosomal proteins (EEA1, early endosome antigen 1, Suppl. Figure 1B) or other Rab proteins, including Rab4 (Suppl. Figure 1C, recycling endosome), Rab21 (Suppl. Figure 1D, early endosome) and Rab7 (Suppl. Figure 1E, late endosome), supporting the selectivity of this phenomenon for Rab5.
Hypoxia increases the association of Rab5 with focal adhesions and stimulates tumor cell migration
It was previously shown that re-localization of Rab5 to the cell periphery leads to the association with focal adhesion (FA) proteins, including FAK, vinculin and paxillin [20, 27]. Thus, we evaluated the possibility that hypoxia enhances the association of Rab5 with FAs. To this end, confocal microscopy analysis was performed revealing a substantial increase in co-localization between GFP-Rab5 and mCherry-paxillin during hypoxia (Manders coefficient: 6.6 ± 0.4% in normoxia versus 20.6 ± 1.1% in hypoxia, Figure 2B). Similar results were obtained when analyzing the co-localization with vinculin, an endogenous FA marker (Figure 2C). These observations were confirmed by immunoprecipitation experiments, as Rab5 was found to co-immunoprecipitate with vinculin and talin (of note, paxillin antibodies were not suitable for Western Blot analysis) and this association was significantly increased during hypoxia (talin, 1.6-fold increase; vinculin, 1.9-fold increase; Figure 2D). Importantly, other related Rab proteins, including Rab11, failed to co-immunoprecipitate with Rab5 and FA proteins under normoxic and hypoxic conditions (Figure 2D and data not shown).
Hypoxia has been shown to activate FAK (i.e. the phosphorylating activation on Y397, [9]) and tumor cell migration by mechanisms that remain elusive [9, 11]. In agreement with those studies, hypoxia promoted A549 cell migration in wound healing (Suppl. Figure 2A) and Boyden Chamber assays (Suppl. Figure 2B), and stimulated FAK phosphorylation on Y397, as a biochemical readout (Suppl. Figure 2C). Of note, the stimulating effects of hypoxia in both cell migration and Rab5 activity were sustained even after re-oxygenation, suggesting an adaptative response towards hypoxia (Suppl. Figure 2B, 2D).
Rab5 activation is required for hypoxia-induced cell migration
Our data indicate that hypoxia promotes Rab5 activation, re-localization to the cell periphery and co-localization with FAs, which is intriguing because the recruitment of Rab5 to FAs was recently shown to precede tumor cell migration and invasion [20]. To evaluate this possibility, endogenous Rab5 was knocked-down by shRNA and cell migration was subsequently determined in wound healing and Boyden Chamber assays. Although the different shRNA sequences used in this study resulted in partial down-regulation of Rab5 (shRNA-B5, 80% decrease; shRNA-F10, 40% decrease), both shRNA sequences provoked a substantial decrease in Rab5-GTP levels to a similar extent (shRNA-B5, 85%; shRNA-F10, 84% decrease) (Figure 3A, 3B). This phenomenon was previously described by our group [20], and is consistent with the notion that a positive-feedback loop for the Rab5 activation cycle exists [29]. Rab5 targeting with both shRNA-B5 and shRNA-F10 inhibited hypoxia-dependent cell migration to a similar extent, as compared to shRNA control cells (Figure 3C, 3D). Importantly, as a control, HIF1α was readily detectable after 24 hours of hypoxia and was not affected by the knock-down of Rab5 (Figure 3A). Our observations showing that Rab5 is activated during hypoxia (Figure 1), along with data indicating that regardless of the effect on total Rab5, both shRNA sequences provoked a similar decrease in Rab5-GTP levels, which paralleled their efficiency in inhibiting cell migration, raised the question as to whether these events are dependent on Rab5 activity. To this end, the response of A549 cells to hypoxia-induced cell migration was evaluated in transfection assays with GFP-Rab5 and the GFP-Rab5/S34N mutant (GDP-bound, inactive Rab5). As expected, transient expression of GFP-Rab5, but not GFP-Rab5/S34N or GFP alone was followed by an increase in cell migration under hypoxic conditions (Figure 3E). Taken together, these data indicate that Rab5 activity is required for hypoxia-dependent cell migration.
Silencing of Rab5 decreases FAK and Rac1 activation induced by hypoxia, without alterations in endocytosis
Because extended exposure to hypoxia was previously suggested to affect endocytosis [13], and given that Rab5 is a central regulator of early endosome dynamics, we evaluated whether hypoxia or Rab5 targeting altered endocytosis of different cargoes. Intriguingly, neither hypoxia nor Rab5 down-regulation affected the internalization of LDL or Tranferrin under these conditions (Figure 4A, 4B), suggesting that the activation of Rab5 during 24 hours of hypoxia does not affect endocytosis in general. Rather, this phenomenon is likely to involve a subset of pathways relevant to cell migration. Since Rab5 is required for β1 integrin function [27, 30, 31] and given that most events evaluated in this study depend on this integrin, we evaluated the expression and activation of β1 integrin. However, neither total nor surface β1 integrin was affected by hypoxia or Rab5 down-regulation (Figure 4C, 4D). Similar results were obtained for surface activated β1 integrin (Figure 4E). On the other hand, the signaling molecules Rac1 and FAK represented interesting alternatives, as both are activated during hypoxia [9, 10] and involved in Rab5-dependent cell migration [20, 22, 23]. As anticipated, hypoxia was found to stimulate FAK phosphorylation on Y397, but this increase depended on Rab5, because shRNA-mediated knock-down prevented the increase in phosphorylation of FAK (Figure 4F). It should be mentioned that FAK activity was functional in these cells and was required for hypoxia induced migration A549 cells, because of treatment with the FAK inhibitor PF 562,271 prevented hypoxia-driven cell migration (Suppl. Figure 3A). To further characterize the signaling pathways implicated in Rab5-dependent cell migration induced by hypoxia, we measured the activity of Rac1, which is known to be activated by Rab5 [22, 23]. As predicted, hypoxia induced a substantial increase in Rac1-GTP levels in cells treated with shRNA-control, but not shRNA-Rab5 (Figure 4G). Given that Rac1 is essential for cellular protrusion and the formation of locomotion structures, we further evaluated the formation of leading edge lamellipodia during hypoxia and their dependence on Rab5. Indeed, hypoxia enhanced the amount of cells with leading edge lamellipodia in shRNA-control, but not shRNA-Rab5 cells (Figure 4H), indicating that Rab5 is necessary for hypoxia-induced Rac1 activation and cell locomotion. Importantly, similar to our previous observations (Figure 3E), expression of GFP-Rab5, but not GFP-Rab5/S34N or GFP alone was sufficient to enhance hypoxia-induced phosphorylation of FAK (Suppl. Figure 3B) and Rac1 activation (Suppl. Figure 3C). Taken together, these data indicate that Rab5 activity is required for FAK and Rac1 signaling induced by hypoxia.
The aggressiveness of tumor cells determines the magnitude of Rab5 activation and migratory capacity induced by hypoxia
Hypoxia is directly associated with the aggressiveness of tumors and it has been shown to be indicative of poor patient prognosis [4]. This raised the question as to whether the effects of hypoxia on Rab5 activity and tumor cell migration depended on the aggressiveness of tumor cells. With this in mind, we evaluated the effect of hypoxia on Rab5 activity and cell migration, by comparing B16-F0 and B16-F10 mouse melanoma cells with low and high metastatic potential, respectively [32]. Intriguingly, hypoxia induced a significant increase in Rab5-GTP levels in B16-F10, but not B16-F0 cells (Figure 5A). Likewise, induction of cell migration by hypoxia was observed in B16-F10, but not B16-F0 cells (Figure 5B). These data suggest that the enhanced sensitivity of metastatic tumor cells towards hypoxia-driven cell migration depends, at least in part, on Rab5 function. To confirm this possibility, we analyzed the effect of expressing different Rab5 mutants in B16-F0 and B16-F10 cells. As suspected, expression of GFP-Rab5 was sufficient to sensitize B16-F0 cells to hypoxia-induced migration, reaching levels similar to B16-F10 cells (Figure 5C). Conversely, expression of GFP-Rab5/S34N prevented the migration of B16-F10 cells exposed to hypoxia (Figure 5C). In agreement with these observations, expression of GFP-Rab5/S34N in B16-F0 failed to increase cell migration induced by hypoxia (data not shown). Taken together, these data suggest that Rab5 expression and its activation are important for the migratory capacity of tumor cells induced by hypoxia.
Hypoxia promotes tumor cell invasion and metastasis in a Rab5 dependent manner
Since hypoxia promotes not only tumor cell migration, but also invasiveness and metastasis [3, 6, 14, 33], we evaluated the requirement of Rab5 in hypoxia-induced tumor cell invasion and metastasis. To this end, B16-F10 mouse melanoma cells were used, as these cells are suitable for evaluating both cell invasion in vitro and metastasis in vivo, in the latter case using syngenic C57BL/6 mice as recipients [32, 33]. The requirement of Rab5 for B16-F10 cell invasion and metastasis was evaluated by shRNA-mediated targeting. In doing so, endogenous Rab5 was down-regulated by 56% in B16-F10 cells with a Rab5-specific shRNA construct, as compared with control shRNA (Figure 6A). Using these cells, we found that hypoxia increased matrigel invasion in shRNA-control, but not shRNA-Rab5 cells (Figure 6B, 6C). Finally, the requirement of Rab5 in hypoxia-induced metastasis in vivo was evaluated by injecting B16-F10 cells into the tail vein of C56BL/6 mice. To this end, B16-F10 cells transduced with shRNA-control or shRNA-Rab5 were exposed to either normoxia or hypoxia for 24 hours, and then injected into mice. In agreement with previous studies [33], 24 hour-exposure to hypoxia was sufficient to enhance lung metastasis of shRNA-control cells (Figure 6D, 6E). Importantly, Rab5 down-regulation prevented both basal metastasis in normoxic conditions and hypoxia-enhanced metastasis (Figure 6D, 6E). It should be noted that under these conditions, cell proliferation and viability were not affected by either Rab5 knock-down or hypoxia (Suppl. Figure 4). Taken together, these data indicate that Rab5 is necessary for B16-F10 tumor cell invasion and metastasis induced by hypoxia.
DISCUSSION
We describe here a novel mechanism by which hypoxia promotes tumor cell migration, invasion and metastasis, via activation of Rab5-dependent signaling. Hypoxia promoted Rab5 activation (i.e. GTP loading) in different tumor cells, including A549 lung carcinoma, ZR-75, MDA-MB-231 and MCF-7 breast cancer and B16-10 mouse melanoma cells. Increased Rab5 activation by hypoxia was followed by its re-localization to the leading edge and co-localization with focal adhesions. In fact, Rab5 was found to be required for hypoxia-induced cell migration, FAK activation, Rac1-GTP loading, invasion and metastasis, as shown by shRNA and reconstitution approaches. An important conclusion from our experiments is that the effect of hypoxia on Rab5 varies according to the aggressiveness of tumor cells. Specifically, hypoxia induced a more robust activation of Rab5 in the more aggressive cell line MCF-7, when compared to ZR-75 cells [34]. However, these cells lines are not necessarily comparable, as they are derived from different patients and have been cultured in different conditions [35, 36]. However, in mouse melanoma cells of the same origin [32], hypoxia activated Rab5 in highly metastatic B16-F10, but not in the poorly metastatic B16-F0 cells. These intriguing observations are in agreement with cell migration data, suggesting that the magnitude of Rab5 activation by hypoxia correlates with the migratory capacity of tumor cells. These provocative findings were further confirmed by data showing that the transfection of B16-F0 cells with wild type Rab5, but not an inactive mutant (Rab5/S34N) enhanced their migratory response towards hypoxia, whereas expression of Rab5/S34N in B16-F10 cells prevented hypoxia-induced migration. These in vitro observations indicate that the activation of Rab5 by hypoxia increases the migratory capacity of tumor cells and provide the initial proof-of-concept that increasing Rab5 activation in poorly metastatic cells favors the acquisition of traits associated with enhanced metastatic potential. Future studies will be required to substantiate this intriguing possibility.
The effects of hypoxia on Rab5 appeared to be selective, because hypoxia failed to affect the localization of other related Rabs, including early endocytic Rab4 and Rab21 and late endocytic Rab7. Intriguingly, previous studies have shown that hypoxia causes re-localization of Rab11 (which resides in recycling endosomes) to the cell periphery [14]. In agreement with those studies, we observed a partial, but noticeable re-localization of Rab11 in A549 cells exposed to hypoxia (Suppl. Figure 1F). However, no Rab11 or other related Rabs were found to co-immunoprecipitate with Rab5 and FA proteins (Figure 2D, data not shown), further indicating the selectivity of this phenomenon. Moreover, we observed that Rab5 activation after 24 hours of hypoxia is neither related to changes in overall endocytosis of LDL (late endosome cargo) nor transferrin (cargo destined to the recycling pathway). These data are in agreement with previous studies showing that hypoxia induces the endocytosis of cargo proteins after 48 hours, but not after 24 hours [13].
Hypoxia promoted not only the activation of Rab5, but also induced its re-localization and association with the FA proteins paxillin and vinculin, although it remains unclear whether this association occurs at the cell surface or rather within early endosomes that contain FA components, as recently described [37]. This is particularly intriguing, since hypoxia provoked a small, but significant increase in early endosome size, as judged by both Rab5 and EEA1 staining (Suppl. Figure 5). Although we cannot exclude the possibility that Rab5 co-localization with FA proteins occurs within early endosomes, it is worth mentioning that no paxillin or very low levels of vinculin were previously detected in early endosome fractions [37]. Our studies provide evidence that these FA proteins co-localize and co-immunoprecipitate with Rab5 in normoxia and that this association was enhanced during hypoxia. In this respect, previous studies from our group have shown that the association of Rab5 with FAs is followed by FA disassembly [20], leading to the possibility that hypoxia-induced activation of Rab5 accelerates the turnover of FAs, in order to sustain tumor cell migration. Although this possibility remains to be evaluated, this study shows that functionally active Rab5 is necessary for hypoxia-induced migration, FAK phosphorylation on Y397 and Rac1-GTP loading.
Finally, Rab5 was required for tumor cell invasion in vitro and metastasis, as shown by matrigel invasion and in vivo assays. Using a syngenic mouse model [32], Rab5 down-regulation in B16-F10 cells prevented the metastasis-promoting effect of hypoxia, which was recently documented [33]. It is important to mention that both enhanced migration in vitro and metastasis in vivo persisted over time and were not affected by re-oxygenation ([33], and this paper). Accordingly, Rab5-GTP levels remained higher after re-oxygenation, suggesting that the activation of Rab5 and the effects on tumor cell migration and metastasis represent adaptive events that may involve de novo protein synthesis. In this respect, hypoxia failed to induce changes in total Rab5 levels at the time-points evaluated, although Rab5-GTP loading by hypoxia depended on HIF-1α, suggesting that adaptative mechanisms for Rab5 regulation are induced by hypoxia. An exciting possibility that remains to be evaluated is that proteins controlling either Rab5 activation or inactivation could be regulated by hypoxia, which might explain the maintenance of Rab5 activation during extended periods of hypoxia and following re-oxygenation.
In summary, this work provides evidence for a novel mechanism by which hypoxia promotes tumor cell migration, invasion and metastasis, via activation of Rab5-dependent signaling. The relevance of Rab5 function in tumor cells with different metastatic potential is suggested, as these events are more pronounced in highly metastatic tumor cells. Future studies will be required to substantiate this intriguing possibility.
MATERIALS AND METHODS
Materials
Monoclonal anti-Rab5 (sc46692), polyclonal anti-Rab5 (sc28570) and antibodies for Rab4 (sc28569), Rab7 (sc10767), Rab11 (sc9020), Rab21 (sc81917), EEA1 (sc33585), FAK (sc1688) and β1 integrin (sc8978) were from Santa Cruz Biotechnology (Santa Cruz, CA). Other antibodies included anti-phospho-Y397-FAK (#3283, Cell Signaling Technology), anti-vinculin (#V4505, Sigma-Aldrich, St. Louis, MO), anti-HIF1α and anti-Rac1 (Transduction Laboratories, Lexington, KY), anti-talin (Chemicon International, MAB1676), and anti-β1 integrin (active conformation, Chemicon International, MAB2079Z). Goat anti-rabbit and goat anti-mouse antibodies coupled to horseradish-peroxidase and anti-actin antibody (#A5316) were from Bio-Rad Laboratories (Hercules, CA). Phalloidin-rhodamine, transfection reagent Lipofectamine 2000, AlexaFluor-488 and AlexaFluor-568 secondary antibodies were from Invitrogen (Carlsbad, CA). Tissue culture medium, antibiotics and fetal bovine serum were from GIBCO Life Technologies (Grand Island, NY) and HyClone Laboratories (Logan, UT). Glutathione-Sepharose 4B was from GE Healthcare (Piscataway, NJ). The EZ-ECL chemiluminescent substrate and protein A/G beads were from Pierce Chemical (Rockford, IL). Rab5 lentiviral short hairpin RNAs (shRNA) were from Open Biosystems (Huntsville, AL). The FAK Inhibitor Compound PF562,271 was from Laviana Corporation, as previously described [38].
Plasmids
The pEGFP-C1 plasmids encoding wild-type Rab5 and Rab5/S34N were kindly provided by Dr. Francisca Bronfman (Pontificia Universidad Católica de Chile, Chile) and previously described [20, 22]. The mCherry-paxillin and pEGFP-C1-actin constructs were kindly provided by Dr. David Schlaepfer (University of California San Diego, USA). The modified pEGFP-C1-mCherry plasmid harboring a deletion of GFP gene sequence, but encoding either mCherry or mCherry-R5BD (the Rab5 Binding Domain, R5BD) were previously described [20].
Cell culture
A549, MDA-MB-231, MCF-7, ZR-75, B16-F0 and B16-F10 cells were cultured in DMEM-high glucose, DMEM-F12 and RPMI media supplemented with 10% FBS and antibiotics, according to the ATCC's instructions. It should be noted that for most studies, A549 cells were used, because these cells were suitable for down-regulation experiments with different shRNA sequences and for transfection experiments with shRNA-resistant Rab5 mutants. Rab5 down-regulation with different shRNA sequences was previously described [20, 39]. Control cells were infected with a lentivirus encoding a nonspecific shRNA sequence (plasmid 1864; Addgene, Cambridge, MA). Rab5 down-regulation was performed by using the shRNA sequences #B5 and #F10 (Open Biosystems) for A549 cells, and sequence #F8 (Open Biosystems) for B16-F10 cells. HIF-1α was down-regulated both stably with shRNA (Cat N° sc-35561-sh, control shRNA Cat N° sc-108060, Santa Cruz Biotechnology, CA) and transiently with siRNA (Cat N° sc-35561, control siRNA Cat N° 37007, Santa Cruz Biotechnology, CA). Stable cell lines were selected and maintained in 2μg/ml puromycin-containing culture medium. Transient Transfections. Cells were grown for 24 hours in complete medium at 50–70% confluence. Transfections were performed with 2 μg of the indicated plasmids (60 mm plates) by using the Lipofectamine 2000 system according to the manufacturer's instructions. Post-transfection, samples were used for analysis by Western blot, fluorescence microscopy and migration assays.
Hypoxia
Cells were cultured in a hermetically sealed, modular incubator chamber (MIC-101 Billups-Rothenberg Inc., Del Mar, CA). This chamber is a widely used model for inducing hypoxic conditions in vitro. The chamber was flushed with a certified gas mixture (1% O2, 5% CO2 and 94% N2, Linde Group®) for 10 minutes at 10 L/min, in order to establish hypoxic conditions, according to the manufacturer instructions. Humidity was reassured in the chamber by placing a plastic petri dish containing 12 mL of sterile water in the chamber. All cells exposed to hypoxia were incubated with hypoxic medium pretreated at least 12 hours prior to assays.
Western blotting
Cells were washed twice with cold PBS and lysed in 0.2 mM HEPES (pH 7.4) buffer containing 0.1% SDS, phosphatase inhibitors (1 mM Na3VO4), as well as a protease inhibitor cocktail. Total protein extracts (50 μg/lane, unless indicated) were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. Blots were blocked with 5% milk in 0.1% Tween-PBS and then probed with antibodies. Bound primary antibodies were detected with HRP-conjugated secondary antibodies and the EZ-ECL system.
Immunofluorescence
Immunofluoresecence was performed as previously described [20]. Vinculin was detected with a monoclonal antibody. Samples were analyzed with a confocal microscope (Carl Zeiss LSM-Pascal 5).
Rab5-GTP and Rac1-GTP pull down assay
Rab5-GTP and Rac1-GTPpull-down assays were performed as previously described [22, 28]. Briefly, cells were lysed in a buffer containing 25 mM HEPES (pH 7.4), 100 mM NaCl, 5 mM MgCl2, 1% NP 40, 10% glycerol, 1 mM dithiothreitol and protease inhibitors. Extracts were incubated for 5 min on ice and clarified by centrifugation (10,000xg, 1 min, 4°C). Post-nuclear supernatants were used for pull-down assays with 30 μg of GSH beads pre-coated with GST-R5BD (Rab5-GTP pull-down) or GST-PBD (Rac1-GTP pull-down) per condition. Beads were incubated with supernatant for 15 min at 4°C in a rotating shaker. Thereafter, beads were collected, washed with lysis buffer containing 0.01% NP 40 and samples were analyzed by Western blotting.
Immunoprecipitation
Rab5 immunoprecipitation was previously described [20]. This method was developed to minimize GTP hydrolysis, optimizing the recovery of active Rab5, by using short incubation periods. Essentially, cell extracts were prepared in a buffer containing 20 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40 and protease inhibitors. After incubation for 5 min on ice, samples were centrifuged at 13,000xg for 1 min at 4°C and post nuclear supernatants (500 μg total protein) were immunoprecipitated with protein A/G bead immobilized polyclonal antibodies for no longer than 30 min. Immunoprecipitated samples were solubilized in Laemmli buffer, boiled, separated by SDS-PAGE and analyzed by Western blotting.
Migration and invasion assays
Cell migration was evaluated in wound healing and Boyden Chamber assays (Transwell Costar, 6.5 mm diameter, 8 μm pore size), whereas invasion was evaluated in Matrigel (BD Biosciences catalog #354480), as previously reported [20, 22]. Cells exposed to hypoxia were harvested and then allowed to migrate in normoxic or hypoxic conditions. Of note, cells were collected in hypoxic pretreated media when migration was evaluated in transwell assays under hypoxic conditions. For wound healing assays, perpendicular cross-shaped wounds were introduced with a p200 pipette tip to monolayers of cells in 24 well plates. All wounded areas were recorded at 40X magnification, by capturing three adjacent images, starting from a distance equivalent to 0.8-1 mm from the cross center (i.e., a total of 12 images were captured per well). Then, plates were placed back into the hypoxic chamber and incubated for 24 h. Wounded areas were recorded at this time point, as described above (12 images per well) and analyzed with Image J.
Cell proliferation and viability assays
Measurements were performed as previously described [39], but important modifications were included. First, experiments were performed in the presence of serum, and second, measurements were done for up to 24 h. MTS assay. Cells were seeded on 96-well plates at a density of 1×104 cells per well and incubated for 24 h under normoxic or hypoxic conditions in complete medium. Optical density (O.D.) was assessed with the MTS® kit, by measuring the absorbance at 490 nm, according to the manufacturer's instructions (Promega, Madison, WI, US). Trypan Blue Exclusion Assay. Cells were seeded on 24-well plates at a density of 1×105 cells per well and incubated for 24 h under normoxic or hypoxic conditions in complete medium. Then, cells were harvested, resuspended and stained with Trypan Blue for counting in the microscope.
Image analysis
Measurement of the percentage of cells with peripheral mCherry
Measurements were performed as previously described [20]. Cells were transiently transfected with mCherry or mCherry-R5BD and GFP-actin and then exposed to normoxia or hypoxia for 24 hours. After fixation, cells were analyzed by confocal microscopy (Carl Zeiss LSM-Pascal 5). Images were randomly chosen, and entire cells were scored as “positive for peripheral mCherry staining” or “negative for peripheral mCherry staining” based on the detection of mCherry signal at the cell periphery. The percentage of “positive cells” was calculated with respect to the total cell number.
Co-localization analysis
Cells were transiently transfected with GFP-Rab5 and mCherry-paxillin and then subjected to normoxia or hypoxia for 24 hours. Co-localization data were evaluated in original images, obtained by Confocal Microscopy (Carl Zeiss LSM-Pascal 5). Analysis was performed with the Image J software, by using the “JACoP” plugin. To this end, the threshold was adjusted in both channels, green for GFP-Rab5 and red for mCherry-paxillin. Additionally, cells were transiently transfected with GFP-Rab5, and vinculin was detected with a specific antibody. In both cases, Mander's coefficients were calculated with respect to GFP-Rab5. At least, 10 images were evaluated per experiment.
Internalization assays
Cells were grown to 60-80% confluence in complete medium for 24 hours. Thereafter, cells were detached with trypsin, centrifuged, re-suspended in 0.2% BSA in DMEM-high glucose plus 10 mM HEPES, pH 7.4 (internalization medium), and incubated for 30 min at 4°C. For internalization experiments, 250 μl of aliquots of cell suspensions (5×105 cells) were placed in 1 ml tubes. Cells were centrifuged and resuspended with 0.2% BSA in internalization medium containing either 30 μg/μl Alexa Fluor®488-labeled transferrin or 10 μg/μl BODIPY®-FL-LDL at 4°C, for 30 min. Incubations were carried out at 37°C and stopped on ice at different time points as indicated. Then, cells were re-suspended in stripping buffer (0.2% BSA in DMEM-high glucose, pH 3.5, adjusted with HCl). Thereafter, cells were washed with ice-cold PBS, fixed with 0.5% paraformaldehyde, and re-suspended with PBS. Samples were analyzed using a fluorescence activated cell sorter (FACSCanto) and data were analyzed with the WinMDI software.
Surface β1 integrin analysis
Cells were grown for 24 h at sub-confluence in complete medium, under normoxic or hypoxic conditions. Thereafter, cells were resuspended in PBS, fixed with 0.4% paraformaldehyde and blocked in 0.5% BSA/PBS for 30 min at 4°C. Samples were then incubated with the antibodies against active or total β1 integrin for 60 min at 4°C, followed by a 30 min incubation with secondary antibodies conjugated to AlexaFluor®488. Finally, cells were resuspended in PBS and analyzed by flow cytometry (FACSCanto; BD Biosciences, Mountain View, CA).
Syngenic metastasis assay
B16-F10 cells were subjected to normoxia or hypoxia for 24 hours and then injected intravenously into the tail vein of C57BL/6 mice (2×105 cells in 500ul physiological saline solution). After 21 days, mice were sacrificed and lungs were fixed in Feketes solution (70% ethanol, 10% formalin, 5% acetic acid glacial). Black tumor masses were separated from the rest of the lung and weighed. Metastasis was expressed as black tissue mass/total lung mass (%) [40]. The experimental protocols employed were approved by the institutional bioethics committee (CBA 0748 CMUCH).
Statistical analysis
Where pertinent, results were compared using unpaired t tests with the GraphPad Prism 5 software (San Diego, CA). Values averaged from at least three independent experiments were compared. A p value < 0.05 was considered significant.
SUPPLEMENTARY FIGURES
Acknowledgments
This work was supported by National Fund for Scientific and Technological Development (FONDECYT) #1140907 (to VAT), CONICYT-FONDAP #15130011 (to VAT, AFGQ), FONDECYT #1130250 (to AQ) and CONICYT PhD fellowships (to PS, SR). We acknowledge Dr. David Schlaepfer for providing us with the mCherry-paxillin and pEGFP-C1-actin constructs.
Footnotes
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
- 1.van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728:23–34. doi: 10.1016/j.mrrev.2011.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. Journal of molecular medicine. 2007;85:1301–1307. doi: 10.1007/s00109-007-0281-3. [DOI] [PubMed] [Google Scholar]
- 3.Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nature reviews Cancer. 2014;14:430–439. doi: 10.1038/nrc3726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. The oncologist. 2008;13(Suppl 3):21–26. doi: 10.1634/theoncologist.13-S3-21. [DOI] [PubMed] [Google Scholar]
- 5.Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis reviews. 2007;26:225–239. doi: 10.1007/s10555-007-9055-1. [DOI] [PubMed] [Google Scholar]
- 6.Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer metastasis reviews. 2007;26:319–331. doi: 10.1007/s10555-007-9062-2. [DOI] [PubMed] [Google Scholar]
- 7.Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nature reviews Cancer. 2012;12:9–22. doi: 10.1038/nrc3183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clinical cancer research. 2007;13:5670–5674. doi: 10.1158/1078-0432.CCR-07-0111. [DOI] [PubMed] [Google Scholar]
- 9.Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D, Semenza GL. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America; 2014; pp. E384–393. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 10.Du J, Xu R, Hu Z, Tian Y, Zhu Y, Gu L, Zhou L. PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1alpha expression in MCF-7 breast cancer cells. PloS one. 2011;6:e25213. doi: 10.1371/journal.pone.0025213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lee JW, Ryu YK, Ji YH, Kang JH, Moon EY. Hypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4. Oncotarget. 2015;6:9820–9833. doi: 10.18632/oncotarget.3218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Misra A, Pandey C, Sze SK, Thanabalu T. Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT) PloS one. 2012;7:e49766. doi: 10.1371/journal.pone.0049766. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, Irwin MS, Kim WY, Teh BT, Grinstein S, Park M, Marsden PA, et al. Regulation of endocytosis via the oxygen-sensing pathway. Nature medicine. 2009;15:319–324. doi: 10.1038/nm.1922. [DOI] [PubMed] [Google Scholar]
- 14.Yoon SO, Shin S, Mercurio AM. Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer research. 2005;65:2761–2769. doi: 10.1158/0008-5472.CAN-04-4122. [DOI] [PubMed] [Google Scholar]
- 15.Jones MC, Caswell PT, Norman JC. Endocytic recycling pathways: emerging regulators of cell migration. Current opinion in cell biology. 2006;18:549–557. doi: 10.1016/j.ceb.2006.08.003. [DOI] [PubMed] [Google Scholar]
- 16.Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nature reviews Cancer. 2008;8:835–850. doi: 10.1038/nrc2521. [DOI] [PubMed] [Google Scholar]
- 17.Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10:513–525. doi: 10.1038/nrm2728. [DOI] [PubMed] [Google Scholar]
- 18.Tang BL, Ng EL. Rabs and cancer cell motility. Cell Motil Cytoskeleton. 2009;66:365–370. doi: 10.1002/cm.20376. [DOI] [PubMed] [Google Scholar]
- 19.Torres VA, Stupack DG. Rab5 in the regulation of cell motility and invasion. Curr Protein Pept Sci. 2011;12:43–51. doi: 10.2174/138920311795659461. [DOI] [PubMed] [Google Scholar]
- 20.Mendoza P, Ortiz R, Diaz J, Quest AF, Leyton L, Stupack D, Torres VA. Rab5 activation promotes focal adhesion disassembly, migration and invasiveness in tumor cells. J Cell Sci. 2013;126:3835–3847. doi: 10.1242/jcs.119727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Palamidessi A, Frittoli E, Ducano N, Offenhauser N, Sigismund S, Kajiho H, Parazzoli D, Oldani A, Gobbi M, Serini G, Di Fiore PP, Scita G, Lanzetti L. The GTPase-activating protein RN-tre controls focal adhesion turnover and cell migration. Current biology. 2013;23:2355–2364. doi: 10.1016/j.cub.2013.09.060. [DOI] [PubMed] [Google Scholar]
- 22.Diaz J, Mendoza P, Ortiz R, Diaz N, Leyton L, Stupack D, Quest AF, Torres VA. Rab5 is required in metastatic cancer cells for Caveolin-1-enhanced Rac1 activation, migration and invasion. J Cell Sci. 2014;127:2401–2406. doi: 10.1242/jcs.141689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Palamidessi A, Frittoli E, Garre M, Faretta M, Mione M, Testa I, Diaspro A, Lanzetti L, Scita G, Di Fiore PP. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell. 2008;134:135–147. doi: 10.1016/j.cell.2008.05.034. [DOI] [PubMed] [Google Scholar]
- 24.Frittoli E, Palamidessi A, Marighetti P, Confalonieri S, Bianchi F, Malinverno C, Mazzarol G, Viale G, Martin-Padura I, Garre M, Parazzoli D, Mattei V, Cortellino S, Bertalot G, Di Fiore PP, Scita G. A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination. The Journal of cell biology. 2014;206:307–328. doi: 10.1083/jcb.201403127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Balaji K, Colicelli J. RIN1 regulates cell migration through RAB5 GTPases and ABL tyrosine kinases. Communicative & integrative biology. 2013;6:e25421. doi: 10.4161/cib.25421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Hu H, Milstein M, Bliss JM, Thai M, Malhotra G, Huynh LC, Colicelli J. Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration. Molecular and cellular biology. 2008;28:1573–1583. doi: 10.1128/MCB.01087-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Torres VA, Mielgo A, Barbero S, Hsiao R, Wilkins JA, Stupack DG. Rab5 mediates caspase-8-promoted cell motility and metastasis. Mol Biol Cell. 2010;21:369–376. doi: 10.1091/mbc.E09-09-0769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Torres VA, Mielgo A, Barila D, Anderson DH, Stupack D. Caspase 8 promotes peripheral localization and activation of Rab5. The Journal of biological chemistry. 2008;283:36280–36289. doi: 10.1074/jbc.M805878200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Del Conte-Zerial P, Brusch L, Rink JC, Collinet C, Kalaidzidis Y, Zerial M, Deutsch A. Membrane identity and GTPase cascades regulated by toggle and cut-out switches. Molecular systems biology. 2008;4:206. doi: 10.1038/msb.2008.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Onodera Y, Nam JM, Hashimoto A, Norman JC, Shirato H, Hashimoto S, Sabe H. Rab5c promotes AMAP1-PRKD2 complex formation to enhance beta1 integrin recycling in EGF-induced cancer invasion. The Journal of cell biology. 2012;197:983–996. doi: 10.1083/jcb.201201065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Sandri C, Caccavari F, Valdembri D, Camillo C, Veltel S, Santambrogio M, Lanzetti L, Bussolino F, Ivaska J, Serini G. The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell research. 2012;22:1479–1501. doi: 10.1038/cr.2012.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer research. 1975;35:218–224. [PubMed] [Google Scholar]
- 33.Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene. 2012;31:2461–2470. doi: 10.1038/onc.2011.425. [DOI] [PubMed] [Google Scholar]
- 34.Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer research. 2001;61:5168–5178. [PubMed] [Google Scholar]
- 35.Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. Journal of the National Cancer Institute. 1973;51:1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
- 36.Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer research. 1978;38:3352–3364. [PubMed] [Google Scholar]
- 37.Alanko J, Mai A, Jacquemet G, Schauer K, Kaukonen R, Saari M, Goud B, Ivaska J. Integrin endosomal signalling suppresses anoikis. Nature cell biology. 2015;17:1412–1421. doi: 10.1038/ncb3250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer research. 2008;68:1935–1944. doi: 10.1158/0008-5472.CAN-07-5155. [DOI] [PubMed] [Google Scholar]
- 39.Silva P, Soto N, Diaz J, Mendoza P, Diaz N, Quest AF, Torres VA. Down-regulation of Rab5 decreases characteristics associated with maintenance of cell transformation. Biochemical and biophysical research communications. 2015;464:642–646. doi: 10.1016/j.bbrc.2015.06.176. [DOI] [PubMed] [Google Scholar]
- 40.Lobos-Gonzalez L, Aguilar L, Diaz J, Diaz N, Urra H, Torres VA, Silva V, Fitzpatrick C, Lladser A, Hoek KS, Leyton L, Quest AF. E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment cell & melanoma research. 2013;26:555–570. doi: 10.1111/pcmr.12085. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.